Search the Newsreel

Ithaca Energy Raises Dividend Guidance Despite Rosebank's Tightened Timeline

Monolithic (MPWR) Financial Update: Reported EPS Tops Expectations in the Latest Reading; Post-Earnings: Shares Fall 2.48% for the Current Session - Book Value Growth

Motor & General Finance Ltd. Revenue Breakdown – NSE:MOTOGENFIN

Zevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC Wainwright

HC Wainwright has reiterated a "Buy" rating for Zevra Therapeutics (NASDAQ:ZVRA) with a $26 price target, suggesting a significant upside. This positive outlook is echoed by other analysts, resulting in a consensus "Moderate Buy" rating and an average target price of $27.14. The company …

Radiopharm advances RAD202 trial to higher dose level By Investing.com

Radiopharm Theranostics has received approval from its Data Safety and Monitoring Committee to increase the dose level of its RAD202 radiotherapeutic to 180mCi in a Phase 1 clinical trial. The trial, named HEAT, is evaluating 177Lu-RAD202 in patients with HER2-positive advanced solid tumors. This …

Is National Health Investors (NHI) Undervalued After Its Earnings And Dividend Update?

National Health Investors (NHI) recently reported higher Q2 2026 revenue and net income, along with a small dividend increase to $0.94 per share. While its 3-year shareholder return is strong, recent performance has been mixed. The company is considered 14.6% undervalued with an implied …

SouthState’s New Government Contractor Banking Push Might Change The Case For Investing In SSB

SouthState Bank has expanded into Government Contractor Banking, appointing David Mathis to lead this new vertical. While this move diversifies the bank's business offerings, the article emphasizes that it doesn't immediately alter the primary investment considerations of deposit costs and commercial real estate exposure …

Why Is American Healthcare REIT (AHR) Back On Investors’ Radar?

American Healthcare REIT (AHR) has garnered renewed investor interest following strong Q2 results, increased revenue and net income, and raised full-year earnings guidance for 2026. Despite a recent share price pullback, the stock has delivered significant year-to-date and one-year returns. While some analyses suggest …

TherapeuticsMD, Inc. Revenue Breakdown – NASDAQ:TXMD

This article provides a revenue breakdown for TherapeuticsMD, Inc. (NASDAQ: TXMD), highlighting that the greatest contribution to its revenue came from the United States, accounting for $1.79 million USD last year and $1.12 million USD the year prior. The data is presented through TradingView, …

Travelers Companies (TRV) Q2 Profit Rebound Puts Its Valuation Back In Focus

Travelers Companies (TRV) reported a strong Q2 2026 profit rebound driven by lower catastrophe losses and higher investment income, leading to an 8.2% share price increase and a 39% one-year total shareholder return. Despite this, a common valuation model suggests TRV is about 4% …

Northern Trust expands First Sentier mandate for $14B Irish fund structure

* Northern Trust Corporation (NTRS [https://seekingalpha.com/symbol/NTRS]) expanded [https://seekingalpha.com/pr/20624978-northern-trust-expands-relationship-with-first-sentier-group-to-support-irish-fund-structure] its relationship with First Sentier Group after being appointed fund administrator and depositary for the asset manager’s $14B Irish fund structure. * Under the mandate, Northern Trust Corporation (NTRS [https://seekingalpha.com/symbol/NTRS]) will provide custody, depositary, fund accounting, …

Cardinal Health CIO Greene sells $2.75m in stock

Michelle D. Greene, CIO of Cardinal Health Inc. (NASDAQ:CAH), sold 11,650 shares for $2.75 million on August 18, 2026, with transactions ranging from $234.07 to $237.32 per share. This sale follows a strong 55% return for Cardinal Health shares over the past year. The …

Black (BDTX) Results Versus Estimates: EPS Comes in Above Forecast for the Current Session; Share Response: The Share Price Adds 6.31% in Latest Trading - Profit Growth Outlook

Las acciones de Sherwin Williams (SHW) parecen sobrevaloradas y con un potencial alcista limitado

Die Aktie von Sherwin Williams (SHW) erscheint überbewertet und bietet nur begrenztes Aufwärtspotenzial

Fathom (FTHM) EPS and Revenue: Reported EPS Misses Expectations in the Latest Session; Market Response: The Stock Ends Up 0.84% on the Day - Low Growth Earnings

Galectin (GALT) Earnings Update: Profit Per Share Falls Below Its Benchmark in the Reported Period; Market Response

Universal Health Services (UHS) Q2 Earnings and Revenues Top Estimates

North Media Q2 2026: Financial results affected by expected volume decline

North Media A/S Selskabsmeddelelse nr. 13-2026 20 August 2026 Martin Frandsen Tobberup, Group CEO of North Media, on the Group's performance in Q2 2026: "Our financial results were affected by an expected volume decline in our distribution businesses. In the underlying business, we further …

Enterprise value to revenue forward of Hightide Therapeutics Inc – HKEX:2511

UBS raises Iovance Biotherapeutics stock price target on revenue beat

Toll Brothers (TOL) Could Be 7% Undervalued Following Earnings Beat And Reaffirmed Guidance

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Toll Brothers (TOL) stock came into focus after the builder reported third quarter results that topped analyst forecasts for revenue and earnings per …

The Bull Case For PTC Therapeutics (PTCT) Could Change Following Renal Data Progress For ST-920

PTC Therapeutics recently discussed the positive regulatory progress of ST-920, supported by Phase 1/2 STAAR data showing significant renal benefits and a favorable safety profile. This development could reshape the company's investment narrative and pipeline, diversifying beyond its current commercial base. While PTC Therapeutics …

VSee Health, Inc. Cash Flow – OTC:VSEEW

VSee Health, Inc. (OTC:VSEEW) reported a negative free cash flow of ‪−1.15 M‬ USD for Q2 2026. For the full year 2025, the company's free cash flow was ‪−3.48 M‬ USD, with operating cash flow at ‪−3.45 M‬ USD. The article provides a high-level …

131,800 Shares in Healthcare Services Group, Inc. $HCSG Bought by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC recently acquired a new stake of 131,800 shares in Healthcare Services Group, Inc. (NASDAQ:HCSG), valued at approximately $3.24 million. Other institutional investors also adjusted their positions in the company, which saw its stock rise by 4.5%. Healthcare Services Group reported …

Fractyl Health to Host Virtual Commercial Strategy Day on

Fractyl Health, Inc. will host a virtual Commercial Strategy Day on September 1, 2026, to discuss the commercial opportunity and go-to-market strategy for Revita, a procedural therapy for post-GLP-1 weight maintenance. This event follows positive one-year data from the REMAIN-1 Midpoint Cohort, which demonstrated …

Cross-Harbour (Holdings) Posts Lower Interim Profit but Ups Second Dividend

Cross-Harbour (Holdings) Declares HKD 0.07 Second-Quarter Dividend for 2026

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

Nurix Therapeutics has appointed Wes Burwell as its new Chief Human Resources Officer. Burwell brings over 20 years of HR leadership experience in the life sciences sector, with a strong background in scaling organizations through growth and preparing for commercialization. His appointment comes as …

Equities Analysts Set Expectations for RNTX FY2026 Earnings

HC Wainwright has updated its FY2026 earnings forecast for Rein Therapeutics (NASDAQ:RNTX), narrowing the projected loss per share to $0.47 from $0.53 and maintaining a "Buy" rating. This adjustment follows Rein Therapeutics' reported quarterly loss of $0.10 per share, which significantly beat analyst expectations. …

Lisanti Capital Growth LLC Acquires Shares of 20,825 Axsome Therapeutics, Inc. $AXSM

Lisanti Capital Growth LLC acquired a new position of 20,825 shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) valued at approximately $5.1 million during the second quarter. This move is part of broader institutional investment, with BlackRock also establishing a significant new position, bringing total institutional …

Gyre Therapeutics (NASDAQ:GYRE) Lowered to "Strong Sell" Rating by Zacks Research

Zacks Research downgraded Gyre Therapeutics (NASDAQ:GYRE) from a "hold" to a "strong sell" rating, with other firms also issuing negative ratings, though the overall analyst consensus remains "hold" with a $17 target price. The company reported a quarterly loss of $0.12 per share, missing …

KeyBanc Maintains American Healthcare REIT(AHR.US) With Buy Rating, Raises Target Price to $68

KeyBanc has reaffirmed its Buy rating for American Healthcare REIT (AHR.US) and increased the target price to $68. This suggests a positive outlook from the firm regarding the company's future performance and stock value.

Bicara Therapeutics (NASDAQ:BCAX) Raised to "Strong-Buy" at BMO Capital Markets

BMO Capital Markets upgraded Bicara Therapeutics (NASDAQ:BCAX) to a "strong-buy" rating, with other analysts maintaining a "Moderate Buy" consensus and an average target price of $32.64. The company's shares rose by 3.8% to $25.86, following a quarterly EPS report of negative $0.82, which met …

Halozyme Therapeutics (HALO) Adds A New Director, Is It 21% Overvalued?

Halozyme Therapeutics (HALO) recently elected Dannielle Appelhans to its Board of Directors, following strong share price returns, increased revenue, and ongoing buybacks. While analysts generally view HALO as 20.7% overvalued with a fair value of $86.89, a Discounted Cash Flow (DCF) model by Simply …

UBS raises J.M. Smucker stock price target to $142 on visibility

UBS has increased its price target for J.M. Smucker Co. (NYSE: SJM) shares to $142 from $130, maintaining a Buy rating. This adjustment comes as J.M. Smucker has significantly outperformed its peers in the packaged food sector year-to-date, with a 29.5% total return. Despite …